Results
1 -
10 of
157Justin M. Holub and Kent Kirshenbaum.
Tricks with clicks: modification of peptidomimetic oligomers via copper-catalyzed azide-alkyne [3 + 2] cycloaddition, Chem. Soc. Rev., 2010, 39, 1325. Arun K. Ghosh, Sandra Gemma, Jun Takayama, Abigail Baldridge, Sofiya Leshchenko-Yashchuk, Heather B. Miller, Yuan-Fang Wang, Andrey Y. Kovalevsky, Yashiro Koh, Irene T. Weber and Hiroaki Mitsuya.
Potent HIV-1protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein–ligand X-ray studies, Org. Biomol. Chem., 2008, 6, 3703. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole, European Journal of Clinical Pharmacology Neither dapsone hydroxylation nor cortisol 6??-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors, European Journal of Clinical Pharmacology Evaluation of Antifungal Activity of Medicinal Plant Extracts Against Oral Candida albicans and Proteinases, Mycopathologia Simultaneous Determination of Six HIV Protease Inhibitors, One Metabolite, and Two Non-nucleoside Reverse Transcriptase Inhibitors in Human Plasma by Isocratic Reversed-Phase Liquid Chromatography After Solid-Phase Extraction, Chromatographia Case Study: Fosamprenavir: A Prodrug of Amprenavir, Prodrugs Aspartic Proteolytic Inhibitors Induce Cellular and Biochemical Alterations in Fungal Cells, Proteases in Health and Disease In Vitro Selection and Characterization of VX-478 Resistant HIV-1 Variants, Aspartic Proteinases In Vivo Selection of HIV-1 Variants with Reduced Susceptibility to the Protease Inhibitor L-735,524 and Related Compounds, Antiviral Chemotherapy 4